NCT02289378.
Trial name or title | Dose‐dense biweekly docetaxel, oxaliplatin and 5‐fluorouracil as first‐line treatment in advanced gastric cancer (DaeMon‐Plus) |
Methods | Phase 2 Intervention Model: Single‐group assignment Masking: Open‐label Primary Purpose: Treatment |
Participants | N = 30 Age 18‐75 years · Participants with histologically or cytologically confirmed unresectable gastric adenocarcinoma whose ECOG performance status are 0‐2 |
Interventions | Experimental: docetaxel, oxaliplatin and 5‐Fu Docetaxel 50 mg/m² Oxaliplatin 85 mg/m² 5‐Fu 2800 mg/m² Repeated every two weeks |
Outcomes | Progression‐free survival [Time frame: 2 years] |
Starting date | November 2014 |
Contact information | Ping Lan, MD The Sixth Affilated Hospital of Sun Yat‐sen University |
Notes |